Mark James Litton is Chief Business Officer at ALDER BIOPHARMACEUTICALS INC (ALDR). They have made 15 open-market trades across 1 company since 2016, most recently 2022-11-18.
CIK 0001423824
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALDR | SELL | 2018-06-01 | 2018-06-05 | $17.84 | $405K | -6.4% | -10.6% | -4.0% |
| ALDR | SELL | 2017-11-13 | 2017-11-15 | $10.80 | $178K | -0.5% | +3.4% | +27.9% |
| ALDR | SELL | 2017-10-16 | 2017-10-18 | $12.33 | $204K | -3.0% | -8.2% | +46.3% |
| ALDR | SELL | 2017-01-18 | 2017-01-20 | $23.10 | $35K | -0.5% | +6.9% | -1.2% |
| ALDR | SELL | 2017-01-06 | 2017-01-09 | $23.02 | $157K | -6.3% | +5.8% | -12.7% |
| ALDR | SELL | 2017-01-05 | 2017-01-09 | $23.00 | $51K | -6.3% | +5.8% | -12.7% |
| ALDR | SELL | 2017-01-05 | 2017-01-09 | $23.01 | $219K | -6.3% | +5.8% | -12.7% |
| ALDR | SELL | 2016-10-17 | 2016-10-19 | $27.50 | $165K | -14.2% | +1.8% | -23.7% |
| ALDR | SELL | 2016-06-13 | 2016-06-15 | $28.90 | $162K | -18.2% | -7.7% | +11.1% |
| ALDR | SELL | 2016-06-13 | 2016-06-15 | $28.93 | $171K | -18.2% | -7.7% | +11.1% |
| ALDR | SELL | 2016-05-31 | 2016-06-01 | $30.05 | $593K | -3.0% | -13.2% | +10.8% |
| ALDR | SELL | 2016-05-27 | 2016-06-01 | $30.06 | $159K | -3.0% | -13.2% | +10.8% |
| ALDR | SELL | 2016-05-27 | 2016-06-01 | $30.05 | $751K | -3.0% | -13.2% | +10.8% |
| ALDR | SELL | 2016-01-04 | 2016-01-06 | $31.40 | $785K | -9.8% | -28.8% | -22.2% |
| ALDR | SELL | 2016-01-04 | 2016-01-06 | $31.40 | $785K | -9.8% | -28.8% | -22.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.